Episodit
-
This week, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases. In the area of business, Hansoh Pharmaceutical Group introduced EGFR/cMet bispecific antibodies, which are expected to link up with Almonertinib in a deal valued at up to RMB1.468 billion. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. All you need to do is getting it registered now and activate your complimentary pass to CPHI & PMEC China Online VEC Event, and access your personal dashboard to connect with potential partners and new suppliers, arrange video meetings, and reserve your spot at expert-led content sessions. Hope you enjoy your VEC journey. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
Next week, you could be networking with thousands of pharma professionals who share your interest in the Chinese market. You could also have access to hours of video content, featuring speeches from some of pharma's most respected and innovative voices. All you need to do is register for Virtual Expo Connect, our online event platform for CPHI & PMEC China. Get it registered now and hope you enjoy your VEC journey. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
Puuttuva jakso?
-
This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
Online registration for CPHI & PMEC China Virtual Expo Connect is in full swing. More than 1000 users have been ready to connect and learn in the world’s second largest pharmaceuticals market. Whether or not you plan to be at CPHI & PMEC in Shanghai, you can join Virtual Expo Connect for free. So, even if you can’t attend the live event, you don’t have to miss out. If you can attend, it’s a great opportunity to extract maximum value from your trip by boosting your networking and visibility. Get it registered now and hope you enjoy your VEC journey. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
This week, the marketing application of HAISCO's first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. Several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients. More pharma news of this week worthy of attention covers topics on drug review, R&D, and Listing. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
Online registration for CPHI & PMEC China Virtual Expo Connect is in full swing. Over the past three weeks, more than 800 users have been ready to connect and learn in the world’s second largest pharmaceuticals market. Whether or not you plan to be at CPHI & PMEC in Shanghai, you can join Virtual Expo Connect for free. So, even if you can’t attend the live event, you don’t have to miss out. If you can attend, it’s a great opportunity to extract maximum value from your trip by boosting your networking and visibility. Get it registered now and hope you enjoy your VEC journey. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
This week, the two most noteworthy news were the approval of the two-drug HIV therapy developed by GSK for marketing in China and the submission of the marketing application for Zevorcabtagene Autoleucel injection of CARsgen, which is the second BCMA CAR-T product to be declared for marketing in China. The results of the Phase I study of Innovent’s GLP-1R/GCGR dual agonist were published, with a weight loss of over 11.5% at 12 weeks of dosing. More pharma news of this week worthy of attention covers topics on drug review, R&D, and Listing. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
The Registration for CPHI & PMEC China online virtual expo connect is open. It may be a few months later than expected but CPHI & PMEC China is finally just around the corner. Whether you can make it in person to Shanghai or not, the online event Virtual Expo Connect will ensure you don’t miss out. Don't forget to get it registered and grow your pharma business online. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
This week, Hua Medicine received marketing approval from China's NMPA for its glucokinase activator Dorzagliatin Tablets to treat type II diabetes It makes the first glucokinase activator drug to gain approval in any market. While in the global market, BeiGene announced that zanubrutinib achieved superior Progression-Free Survival (PFS) versus ibrutinib in a final analysis of the Phase 3 ALPINE trial, as assessed by an independent review committee and investigator. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
The Registration for CPHI & PMEC China online virtual expo connect is open. You can sign up on PharmaSources.com to participate in the event now. Don't miss out the excellent chance to connect with over 2,500 suppliers at the heart of Pharma! Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)
-
This week, in the Chinese pharma market, Humanwell Healthcare's first generic drug of oxycodone hydrochloride sustained release tablets were approved for marketing; Zelgen Biopharmaceuticals' Jaktinib, the first JAK inhibitor made in China, was declared for marketing, and LEGN.US' Cilta-cel, a BCMA CAR-T cell therapy, was approved in Japan. In terms of R&D, Eisai and Biogen announced positive results from the Phase III trial of Lecanemab to treat Alzheimer's disease (AD). More pharma news of this week worthy of attention covers topics on drug review, R&D, business, and policy. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
This week, in China, Nanjing Biosnwill Pharma's Class 2.2 new drug Edaravone Sublingual Tablets and Yichang Humanwell's Class 3 generic drug Clobazam Tablets have been approved by the NMPA for marketing. Meanwhile, new indications have been approved for both Junshi Biosciences' Toripalimab and AstraZeneca's Olaparib Tablets; New progress with the EMA and FDA approvals has been achieved for some popular drugs. For example, Roche's bispecific antibody ophthalmic drug Faricimab has been approved for marketing in the EU. Although there has been nothing new in R&D during the week, on the business side, Chiatai Tianqing entered into a collaboration agreement with Inventiva for the development of lanifibranor, a pan-PPAR agonist. Besides, InnoCare Pharma was successfully listed on the STAR.
Other pharma news collected this week features 25 pieces of information covering topics on drug review, R&D, business and listing. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
This week, in China, Humanwell Healthcare's Class 1.2 traditional Chinese medicine was approved for marketing. Pearl Bio's Bozitinib enteric capsule was planned to be included for priority approval. Several new drugs were approved for clinical trial stages, or the applications for such trials were submitted. While globally, the terlipressin injection became the world's first FDA-approved therapy to improve renal function in adult patients with hepatorenal syndrome (HRS). Besides, several drugs have obtained Fast Track Designation (FTD), and many innovative drugs achieved positive clinical results, despite the fact that there were also a few drug failures.
Other pharma news collected this week features 26 pieces of information covering topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
This week, the most noteworthy event is Eli Lilly's hypoglycemic drug tirzepatide, a GIP/GLP-1 double agonist, was declared for marketing in China. In the meanwhile, there comes some good news for clinical trial applications of various important drugs. On the R&D side, the pivotal Phase III clinical trials of several drugs have shown positive results, which are related to thyroid carcinoma, pulmonary interstitial fibrosis, migraine, plaque psoriasis, and other indications. Other pharma news collected this week features 25 pieces of information covering topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
The marketing approval of SinoCellTech's new anti-CD20 monoclonal antibody ripertamab aroused the attention of the industry in China this week. While the clinical trial application of the AK130 injection developed by another Chinese company Akeso was accepted, making it the first and the only TIGIT/TGFβ bispecific antibody under research in the world. Other pharma news collected this week features 26 pieces of information covering topics on drug review, R&D, business, and listing. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
In the last week's Chinese pharma market, the 11th indication of BeiGene’s PD-1 Tislelizumab was declared for marketing for the treatment of esophageal squamous cell carcinoma. While in the global pharma market, Johnson & Johnson’s Teclistamab was approved by the EC, making it the first BCMA/CD3 bispecific antibody approved for marketing worldwide. In addition, the EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. Other pharma news collected in this episode covers 4 sections including drug review, R&D, business, and policy. You can get more industry insights and firsthand market information from China to the globe at PharmaSources.com
-
Hey! This is Weekly Pharma News Review from PharmaVibe. I'm Billy. It's been a long time since our last episode. I hope all of you' re doing well and thank you for joining us today. In the last week's Chinese pharma market, Alphamab Oncology’s JSKN003 injection became the first Chinese bispecific antibody ADC declared for clinical use. While in the global pharma market, AstraZeneca/Daiichi Sankyo, Novartis and Sanofi all provide update on their clinical development programs. You can access the full version on Access the full transcript and more fresh content at www.pharmasources.com and enjoy more firsthand market information in the Chinese and global markets.
